Logo

Biocon to Acquire Viatris’ Biosimilars Assets for ~$3.335B

Share this

M&A

Biocon to Acquire Viatris’ Biosimilars Assets for ~$3.335B

Shots:

  • Viatris to receive ~$3.335B including $2B in cash & ~$335M as additional fees expected to be paid in 2024, $1B of CCPS equivalent to an equity stake of 12.9%. The transaction is expected to be close in H2’22
  • The acquisition provides BBL full ownership of Viatris’ rights in biosimilars assets to recognize combined revenues & profits. BBL will gain access to a portfolio of biosimilars in insulin, oncology & immunology along with multiple other biosimilar assets
  • Viatris will provide commercial & transition services to BBL for 2yrs. Biocon will also gain access to Viatris’ global biosimilars business whose revenues are estimated at $1B in 2023 along with in-licensed biosimilar assets

Ref: Biocon | Image: Viatris

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions